Type
1.
Alferink M, Werf T, Sopoh G, Agossadou D, Barogui Y, Assouto F, et al. Perceptions on the effectiveness of treatment and the timeline of Buruli Ulcer influence pre-hospital delay reported by healthy individuals. PLoS Negl Trop Dis [Internet]. 2013;7:e2014. Available from: http://dx.doi.org/10.1371%2Fjournal.pntd.0002014
Type
1.
World Health Organization. Sustaining the drive to overcome the global impact of neglected tropical diseases: Second WHO report on neglected diseases. [Internet]. 1st ed. WHO report on neglected tropical diseases. Geneva, Switzerland: World Health Organization; 2013 p. 139 p. Report No.: WHO/HTM/NTD/2013.1. Available from: http://apps.who.int/iris/bitstream/10665/80245/1/WHO_HTM_NTD_2013.2_eng.pdf
Type
1.
World Health Organization. Accelerating work to overcome the global impact of neglected tropical diseases: A roadmap for implementation: Executive summary. [Internet]. 1 st ed. Geneva: World Health Organization ; 2012 p. 15 p. Report No.: WHO/HTM/NTD/2012.1. Available from: https://apps.who.int/iris/bitstream/handle/10665/70809/WHO_HTM_NTD_2012.1_eng.pdf?sequence=1&isAllowed=y
Type
1.
Beissner M, Huber KL, Badziklou K, Halatoko WA, Maman I, Vogel F, et al. Implementation of a National Reference Laboratory for buruli ulcer disease in Togo. PLoS Negl Trop Dis [Internet]. 2013;7:e2011. Available from: http://dx.doi.org/10.1371%2Fjournal.pntd.0002011
Type
1.
Asiedu, Phillips, Sarfo, Abass, Abotsi, Wilson, et al. Clinical and bacteriological efficacy of Rifampin-Streptomycin combination for two weeks followed by Rifampin and Clarithromycin for six weeks for treatment of mycobacterium ulcerans disease. Antimicrobial agents and chemotherapy. 2014;58(2):1161-6.
Type
1.
Bretzel G, Adjei O, Beissner M, Huber KL, Badziklou K, Maman I, et al. Molecular determination of Rifampicin resistance in clinical samples of patients with buruli ulcer disease: A comparison of two assays. Journal of clinical microbiology [Internet]. 2014; Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3993512/pdf/zjm1246.pdf
Type
1.
Sarfo FS, Converse P, Almeida D, Zhang J, Robinson C, Wansbrough-Jones M, et al. Microbiological, histological, immunological, and toxin response to antibiotic treatment in the mouse model of Mycobacterium ulcerans disease. PLoS neglected tropical diseases [Internet]. 2013;7(3):e2101. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3597478/pdf/pntd.0002101.pdf
Type
1.
Nakanaga K, Yotsu RR, Hoshino Y, Suzuki K, Makino M, Ishii N. Buruli ulcer and mycolactone-producing mycobacteria. Japanese journal of infectious diseases [Internet]. 2013;66(2):83-8. Available from: https://www.jstage.jst.go.jp/article/yoken/66/2/66_83/_pdf
Type
1.
Bratschi M, Bolz M, Minyem J, Grize L, Wantong F, Kerber S, et al. Geographic distribution, age pattern and sites of lesions in a cohort of Buruli ulcer patients from the Mapé Basin of Cameroon. PLoS neglected tropical diseases [Internet]. 2013;7(6):e2252. Available from: http://journals.plos.org/plosntds/article/asset?id=10.1371%2Fjournal.pntd.0002252.PDF
Type
1.
Deutsche Lepra- und Tuberkulosehilfe. DAHW : Jahresberichte [Internet]. Deutsche Lepra- und Tuberkulosehilfe; 2012. Available from: http://www.dahw.de/die-dahw/jahresberichte-der-taetigkeit-der-dahw-nach-laendern
Pagination
- Previous page
- Page 12
- Next page